Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
04
04
2022
accepted:
03
05
2022
pubmed:
27
5
2022
medline:
24
9
2022
entrez:
26
5
2022
Statut:
ppublish
Résumé
This study sought to determine the likelihood of occult malignancy during risk-reducing mastectomy in high-penetrance pathogenic variant carriers to help refine axillary staging recommendations. The authors performed a retrospective cohort study analyzing all female carriers of pathogenic variants in BRCA1/2, PALB2 or other genes who underwent prophylactic surgery at their institution between 2006 and 2021. Occult breast cancer was defined as the unanticipated presence of in situ or invasive malignancy on pathologic evaluation of prophylactic mastectomy specimens. Of 523 women, 243 carriers met the inclusion criteria for the study including 124 BRCA1 (51.0%), 108 BRCA2 (44.4%), and 11 PALB2, TP53, CDH1, or PTEN (4.6%) carriers. The median age was 44 years (interquartile range, 37-52 years). Overall, 128 women (52.7%) underwent bilateral prophylactic mastectomies, and 115 (47.3%) underwent contralateral prophylactic mastectomy. In the 371 mastectomies performed, 16 (4.3%) occult malignancies were diagnosed. Most of the occult malignancies were ductal carcinoma in situ (13 mastectomies, 3.5%), whereas 3 mastectomies (0.8%) contained invasive breast cancer. If Breast Imaging Reporting and Data System (BIRADS) 1-2 or BIRADS 3 findings were reported on preoperative magnetic resonance imaging (MRI), the rate of occult malignancy decreased to 3.0 and 2.8%, respectively, per mastectomy. The patient-level factors associated with a likelihood of occult breast cancer greater than 10% included a history of prior breast cancer, age exceeding 60 years, and BIRADS 4 findings on preoperative imaging. Occult invasive malignancy was detected in less than 1% of the risk-reducing mastectomies performed for women with BRCA1/2 or PALB2 pathogenic variants. Sentinel lymph node biopsy can be safely avoided when BIRADS 1-3 findings are reported on preoperative MRI.
Sections du résumé
BACKGROUND
BACKGROUND
This study sought to determine the likelihood of occult malignancy during risk-reducing mastectomy in high-penetrance pathogenic variant carriers to help refine axillary staging recommendations.
METHODS
METHODS
The authors performed a retrospective cohort study analyzing all female carriers of pathogenic variants in BRCA1/2, PALB2 or other genes who underwent prophylactic surgery at their institution between 2006 and 2021. Occult breast cancer was defined as the unanticipated presence of in situ or invasive malignancy on pathologic evaluation of prophylactic mastectomy specimens.
RESULTS
RESULTS
Of 523 women, 243 carriers met the inclusion criteria for the study including 124 BRCA1 (51.0%), 108 BRCA2 (44.4%), and 11 PALB2, TP53, CDH1, or PTEN (4.6%) carriers. The median age was 44 years (interquartile range, 37-52 years). Overall, 128 women (52.7%) underwent bilateral prophylactic mastectomies, and 115 (47.3%) underwent contralateral prophylactic mastectomy. In the 371 mastectomies performed, 16 (4.3%) occult malignancies were diagnosed. Most of the occult malignancies were ductal carcinoma in situ (13 mastectomies, 3.5%), whereas 3 mastectomies (0.8%) contained invasive breast cancer. If Breast Imaging Reporting and Data System (BIRADS) 1-2 or BIRADS 3 findings were reported on preoperative magnetic resonance imaging (MRI), the rate of occult malignancy decreased to 3.0 and 2.8%, respectively, per mastectomy. The patient-level factors associated with a likelihood of occult breast cancer greater than 10% included a history of prior breast cancer, age exceeding 60 years, and BIRADS 4 findings on preoperative imaging.
CONCLUSIONS
CONCLUSIONS
Occult invasive malignancy was detected in less than 1% of the risk-reducing mastectomies performed for women with BRCA1/2 or PALB2 pathogenic variants. Sentinel lymph node biopsy can be safely avoided when BIRADS 1-3 findings are reported on preoperative MRI.
Identifiants
pubmed: 35616744
doi: 10.1245/s10434-022-11916-3
pii: 10.1245/s10434-022-11916-3
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6660-6668Subventions
Organisme : Fonds de Recherche du Québec - Santé
ID : 309854
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006;107:1440–7.
doi: 10.1002/cncr.22176
Murphy BL, Glasgow AE, Keeney GL, Habermann EB, Boughey JC. Selective use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy using intraoperative pathology. Ann Surg Oncol. 2017;24:3032–7.
doi: 10.1245/s10434-017-5925-0
Bunting PW, Cyr AE, Gao F, Margenthaler JA. Sentinel lymph node biopsy during prophylactic mastectomy: is there a role? J Surg Oncol. 2014;109:747–50.
doi: 10.1002/jso.23575
Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140:135–42.
doi: 10.1007/s10549-013-2583-1
Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer. 2003;97:1601–8.
doi: 10.1002/cncr.11225
Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159–64.
doi: 10.1056/NEJM200107193450301
van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93:287–92.
doi: 10.1038/sj.bjc.6602703
Yamauchi H, Okawa M, Yokoyama S, et al. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan. Breast Cancer Res Treat. 2018;172:679–87.
doi: 10.1007/s10549-018-4953-1
Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015;22:370–6.
doi: 10.1245/s10434-014-3883-3
Camara S, Pereira D, Andre S, et al. The use of sentinel lymph node biopsy in BRCA1/2 mutation carriers undergoing prophylactic mastectomy: a retrospective consecutive case-series study. Int J Breast Cancer. 2018;2018:1426369.
doi: 10.1155/2018/1426369
Haffty BG, Euhus DM, Pierce LJ. Genetic factors in the locoregional management of breast cancer. J Clin Oncol. 2020;38:2220–9.
doi: 10.1200/JCO.19.02859
Pilewskie M, Stempel M, Rosenfeld H, Eaton A, Van Zee KJ, Morrow M. Do LORIS trial eligibility criteria identify a ductal carcinoma in situ patient population at low risk of upgrade to invasive carcinoma? Ann Surg Oncol. 2016;23:3487–93.
doi: 10.1245/s10434-016-5268-2
Grimm LJ, Ryser MD, Partridge AH, et al. Surgical upstaging rates for vacuum-assisted biopsy proven DCIS: implications for active surveillance trials. Ann Surg Oncol. 2017;24:3534–40.
doi: 10.1245/s10434-017-6018-9
Gentilini O, Botteri E, Dadda P, et al. Physical function of the upper limb after breast cancer surgery. results from the SOUND (Sentinel Node vs Observation After Axillary Ultra-souND) trial. Eur J Surg Oncol. 2016;42:685–9.
doi: 10.1016/j.ejso.2016.01.020
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–62.
doi: 10.1200/JCO.2004.04.188
Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14:3335–44.
doi: 10.1245/s10434-007-9449-x
Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 2014;21:37–41.
doi: 10.1245/s10434-013-3230-0
McLaughlin SA, Stempel M, Morris EA, Liberman L, King TA. Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer. 2008;112:1214–21.
doi: 10.1002/cncr.23298
Taliaferro AS, Price ER, Hayward JH, et al. Utility and outcomes of preoperative screening breast MRI for planned bilateral prophylactic mastectomy in high-risk patients. AJR Am J Roentgenol. 2022;218:241–8.
doi: 10.2214/AJR.21.26561
Poortmans PM, Weltens C, Fortpied C, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21:1602–10.
doi: 10.1016/S1470-2045(20)30472-1
Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–16.
doi: 10.1056/NEJMoa1415340
de Gregorio A, Janni W, Friedl TWP, et al. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer: a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer. 2022.
Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–405.
doi: 10.1056/NEJMoa2105215
Karakatsanis A, Hersi AF, Pistiolis L, et al. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). Br J Surg. 2019;106:720–8.
doi: 10.1002/bjs.11110
Karam A, Stempel M, Cody HS III, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy. J Am Coll Surg. 2008;207:543–8.
doi: 10.1016/j.jamcollsurg.2008.06.139
Vicini E, Leonardi MC, Fontana SKR, et al. How to perform repeat sentinel node biopsy safely after a previous mastectomy: technical features and oncologic outcomes. Ann Surg Oncol. 2022;29:1750–60.
doi: 10.1245/s10434-021-10986-z
Vugts G, Maaskant-Braat AJ, Voogd AC, et al. Improving the success rate of repeat sentinel node biopsy in recurrent breast cancer. Ann Surg Oncol. 2015;22(Suppl 3):S529–35.
doi: 10.1245/s10434-015-4787-6